Literature DB >> 16251343

Improved outcomes with linezolid for methicillin-resistant Staphylococcus aureus infections: better drug or reduced vancomycin susceptibility?

Benjamin P Howden, Patrick G P Charles, Paul D R Johnson, Peter B Ward, M Lindsay Grayson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16251343      PMCID： PMC1280171          DOI： 10.1128/AAC.49.11.4816-4817.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  9 in total

1.  Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.

Authors:  Benjamin P Howden; Peter B Ward; Patrick G P Charles; Tony M Korman; Andrew Fuller; Philipp du Cros; Elizabeth A Grabsch; Sally A Roberts; Jenny Robson; Kerry Read; Narin Bak; James Hurley; Paul D R Johnson; Arthur J Morris; Barrie C Mayall; M Lindsay Grayson
Journal:  Clin Infect Dis       Date:  2004-01-29       Impact factor: 9.079

Review 2.  Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.

Authors:  Catherine Liu; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 3.  Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective.

Authors:  B P Howden; P B Ward; P D R Johnson; P G P Charles; M L Grayson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

Review 4.  Vancomycin-resistant staphylococci and enterococci: epidemiology and control.

Authors:  Fred C Tenover; L Clifford McDonald
Journal:  Curr Opin Infect Dis       Date:  2005-08       Impact factor: 4.915

5.  Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.

Authors:  John Weigelt; Kamal Itani; Dennis Stevens; William Lau; Matthew Dryden; Charles Knirsch
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

Review 6.  Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance.

Authors:  K Hiramatsu
Journal:  Lancet Infect Dis       Date:  2001-10       Impact factor: 25.071

Review 7.  The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus.

Authors:  Timothy R Walsh; Robin A Howe
Journal:  Annu Rev Microbiol       Date:  2002-01-30       Impact factor: 15.500

8.  Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.

Authors:  Patrick G P Charles; Peter B Ward; Paul D R Johnson; Benjamin P Howden; M Lindsay Grayson
Journal:  Clin Infect Dis       Date:  2004-01-12       Impact factor: 9.079

9.  Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.

Authors:  Richard G Wunderink; Jordi Rello; Sue K Cammarata; Rodney V Croos-Dabrera; Marin H Kollef
Journal:  Chest       Date:  2003-11       Impact factor: 9.410
  9 in total
  2 in total

1.  Managing Severe Community-Acquired Pneumonia Due to Community Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  Jason C Kwong; Kyra Chua; Patrick G P Charles
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

2.  Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA.

Authors:  Anne Yusof; Anette Engelhardt; Asa Karlsson; Lina Bylund; Pamela Vidh; Karen Mills; Mandy Wootton; Timothy R Walsh
Journal:  J Clin Microbiol       Date:  2008-07-02       Impact factor: 5.948
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.